Analytical performance characteristics of the cepheid GeneXpert Ebola Assay for the detection of Ebola virus

Benjamin A. Pinsky, Malaya K. Sahoo, Johanna Sandlund, Marika Kleman, Medha Kulkarni, Per Grufman, Malin Nygren, Robert Kwiatkowski, Ellen Jo Baron, Fred Tenover, Blake Denison, Russell Higuchi, Reuel Van Atta, Neil Reginald Beer, Alda Celena Carrillo, Pejman Naraghi-Arani, Chad Mire, Charlene Ranadheera, Allen Grolla, Nina Lagerqvist & 1 others David H. Persing

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: The recently developed Xpert® Ebola Assay is a novel nucleic acid amplification test for simplified detection of Ebola virus (EBOV) in whole blood and buccal swab samples. The assay targets sequences in two EBOV genes, lowering the risk for new variants to escape detection in the test. The objective of this report is to present analytical characteristics of the Xpert® Ebola Assay on whole blood samples. Methods and Findings: This study evaluated the assay's analytical sensitivity, analytical specificity, inclusivity and exclusivity performance in whole blood specimens. EBOV RNA, inactivated EBOV, and infectious EBOV were used as targets. The dynamic range of the assay, the inactivation of virus, and specimen stability were also evaluated. The lower limit of detection (LoD) for the assay using inactivated virus was estimated to be 73 copies/mL (95% CI: 51-97 copies/mL). The LoD for infectious virus was estimated to be 1 plaque-forming unit/mL, and for RNA to be 232 copies/mL (95% CI 163-302 copies/mL). The assay correctly identified five different Ebola viruses, Yambuku-Mayinga, Makona-C07, Yambuku-Ecran, Gabon-Ilembe, and Kikwit-956210, and correctly excluded all non-EBOV isolates tested. The conditions used by Xpert® Ebola for inactivation of infectious virus reduced EBOV titer by >6 logs. Conclusion: In summary, we found the Xpert1 Ebola Assay to have high analytical sensitivity and specificity for the detection of EBOV in whole blood. It offers ease of use, fast turnaround time, and remote monitoring. The test has an efficient viral inactivation protocol, fulfills inclusivity and exclusivity criteria, and has specimen stability characteristics consistent with the need for decentralized testing. The simplicity of the assay should enable testing in a wide variety of laboratory settings, including remote laboratories that are not capable of performing highly complex nucleic acid amplification tests, and during outbreaks where time to detection is critical.

Original languageEnglish (US)
Article numbere0142216
JournalPLoS One
Volume10
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Ebolavirus
Viruses
Assays
assays
Virus Inactivation
detection limit
Nucleic Acid Amplification Techniques
analytical specificity
viruses
inactivation
blood
Blood
testing
Limit of Detection
nucleic acids
Gabon
RNA
Sensitivity and Specificity
Cheek
Nucleic Acids

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Pinsky, B. A., Sahoo, M. K., Sandlund, J., Kleman, M., Kulkarni, M., Grufman, P., ... Persing, D. H. (2015). Analytical performance characteristics of the cepheid GeneXpert Ebola Assay for the detection of Ebola virus. PLoS One, 10(11), [e0142216]. https://doi.org/10.1371/journal.pone.0142216

Analytical performance characteristics of the cepheid GeneXpert Ebola Assay for the detection of Ebola virus. / Pinsky, Benjamin A.; Sahoo, Malaya K.; Sandlund, Johanna; Kleman, Marika; Kulkarni, Medha; Grufman, Per; Nygren, Malin; Kwiatkowski, Robert; Baron, Ellen Jo; Tenover, Fred; Denison, Blake; Higuchi, Russell; Van Atta, Reuel; Beer, Neil Reginald; Carrillo, Alda Celena; Naraghi-Arani, Pejman; Mire, Chad; Ranadheera, Charlene; Grolla, Allen; Lagerqvist, Nina; Persing, David H.

In: PLoS One, Vol. 10, No. 11, e0142216, 01.11.2015.

Research output: Contribution to journalArticle

Pinsky, BA, Sahoo, MK, Sandlund, J, Kleman, M, Kulkarni, M, Grufman, P, Nygren, M, Kwiatkowski, R, Baron, EJ, Tenover, F, Denison, B, Higuchi, R, Van Atta, R, Beer, NR, Carrillo, AC, Naraghi-Arani, P, Mire, C, Ranadheera, C, Grolla, A, Lagerqvist, N & Persing, DH 2015, 'Analytical performance characteristics of the cepheid GeneXpert Ebola Assay for the detection of Ebola virus', PLoS One, vol. 10, no. 11, e0142216. https://doi.org/10.1371/journal.pone.0142216
Pinsky, Benjamin A. ; Sahoo, Malaya K. ; Sandlund, Johanna ; Kleman, Marika ; Kulkarni, Medha ; Grufman, Per ; Nygren, Malin ; Kwiatkowski, Robert ; Baron, Ellen Jo ; Tenover, Fred ; Denison, Blake ; Higuchi, Russell ; Van Atta, Reuel ; Beer, Neil Reginald ; Carrillo, Alda Celena ; Naraghi-Arani, Pejman ; Mire, Chad ; Ranadheera, Charlene ; Grolla, Allen ; Lagerqvist, Nina ; Persing, David H. / Analytical performance characteristics of the cepheid GeneXpert Ebola Assay for the detection of Ebola virus. In: PLoS One. 2015 ; Vol. 10, No. 11.
@article{1e0c49238bbb49f98c827fa1d627c10e,
title = "Analytical performance characteristics of the cepheid GeneXpert Ebola Assay for the detection of Ebola virus",
abstract = "Background: The recently developed Xpert{\circledR} Ebola Assay is a novel nucleic acid amplification test for simplified detection of Ebola virus (EBOV) in whole blood and buccal swab samples. The assay targets sequences in two EBOV genes, lowering the risk for new variants to escape detection in the test. The objective of this report is to present analytical characteristics of the Xpert{\circledR} Ebola Assay on whole blood samples. Methods and Findings: This study evaluated the assay's analytical sensitivity, analytical specificity, inclusivity and exclusivity performance in whole blood specimens. EBOV RNA, inactivated EBOV, and infectious EBOV were used as targets. The dynamic range of the assay, the inactivation of virus, and specimen stability were also evaluated. The lower limit of detection (LoD) for the assay using inactivated virus was estimated to be 73 copies/mL (95{\%} CI: 51-97 copies/mL). The LoD for infectious virus was estimated to be 1 plaque-forming unit/mL, and for RNA to be 232 copies/mL (95{\%} CI 163-302 copies/mL). The assay correctly identified five different Ebola viruses, Yambuku-Mayinga, Makona-C07, Yambuku-Ecran, Gabon-Ilembe, and Kikwit-956210, and correctly excluded all non-EBOV isolates tested. The conditions used by Xpert{\circledR} Ebola for inactivation of infectious virus reduced EBOV titer by >6 logs. Conclusion: In summary, we found the Xpert1 Ebola Assay to have high analytical sensitivity and specificity for the detection of EBOV in whole blood. It offers ease of use, fast turnaround time, and remote monitoring. The test has an efficient viral inactivation protocol, fulfills inclusivity and exclusivity criteria, and has specimen stability characteristics consistent with the need for decentralized testing. The simplicity of the assay should enable testing in a wide variety of laboratory settings, including remote laboratories that are not capable of performing highly complex nucleic acid amplification tests, and during outbreaks where time to detection is critical.",
author = "Pinsky, {Benjamin A.} and Sahoo, {Malaya K.} and Johanna Sandlund and Marika Kleman and Medha Kulkarni and Per Grufman and Malin Nygren and Robert Kwiatkowski and Baron, {Ellen Jo} and Fred Tenover and Blake Denison and Russell Higuchi and {Van Atta}, Reuel and Beer, {Neil Reginald} and Carrillo, {Alda Celena} and Pejman Naraghi-Arani and Chad Mire and Charlene Ranadheera and Allen Grolla and Nina Lagerqvist and Persing, {David H.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1371/journal.pone.0142216",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Analytical performance characteristics of the cepheid GeneXpert Ebola Assay for the detection of Ebola virus

AU - Pinsky, Benjamin A.

AU - Sahoo, Malaya K.

AU - Sandlund, Johanna

AU - Kleman, Marika

AU - Kulkarni, Medha

AU - Grufman, Per

AU - Nygren, Malin

AU - Kwiatkowski, Robert

AU - Baron, Ellen Jo

AU - Tenover, Fred

AU - Denison, Blake

AU - Higuchi, Russell

AU - Van Atta, Reuel

AU - Beer, Neil Reginald

AU - Carrillo, Alda Celena

AU - Naraghi-Arani, Pejman

AU - Mire, Chad

AU - Ranadheera, Charlene

AU - Grolla, Allen

AU - Lagerqvist, Nina

AU - Persing, David H.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background: The recently developed Xpert® Ebola Assay is a novel nucleic acid amplification test for simplified detection of Ebola virus (EBOV) in whole blood and buccal swab samples. The assay targets sequences in two EBOV genes, lowering the risk for new variants to escape detection in the test. The objective of this report is to present analytical characteristics of the Xpert® Ebola Assay on whole blood samples. Methods and Findings: This study evaluated the assay's analytical sensitivity, analytical specificity, inclusivity and exclusivity performance in whole blood specimens. EBOV RNA, inactivated EBOV, and infectious EBOV were used as targets. The dynamic range of the assay, the inactivation of virus, and specimen stability were also evaluated. The lower limit of detection (LoD) for the assay using inactivated virus was estimated to be 73 copies/mL (95% CI: 51-97 copies/mL). The LoD for infectious virus was estimated to be 1 plaque-forming unit/mL, and for RNA to be 232 copies/mL (95% CI 163-302 copies/mL). The assay correctly identified five different Ebola viruses, Yambuku-Mayinga, Makona-C07, Yambuku-Ecran, Gabon-Ilembe, and Kikwit-956210, and correctly excluded all non-EBOV isolates tested. The conditions used by Xpert® Ebola for inactivation of infectious virus reduced EBOV titer by >6 logs. Conclusion: In summary, we found the Xpert1 Ebola Assay to have high analytical sensitivity and specificity for the detection of EBOV in whole blood. It offers ease of use, fast turnaround time, and remote monitoring. The test has an efficient viral inactivation protocol, fulfills inclusivity and exclusivity criteria, and has specimen stability characteristics consistent with the need for decentralized testing. The simplicity of the assay should enable testing in a wide variety of laboratory settings, including remote laboratories that are not capable of performing highly complex nucleic acid amplification tests, and during outbreaks where time to detection is critical.

AB - Background: The recently developed Xpert® Ebola Assay is a novel nucleic acid amplification test for simplified detection of Ebola virus (EBOV) in whole blood and buccal swab samples. The assay targets sequences in two EBOV genes, lowering the risk for new variants to escape detection in the test. The objective of this report is to present analytical characteristics of the Xpert® Ebola Assay on whole blood samples. Methods and Findings: This study evaluated the assay's analytical sensitivity, analytical specificity, inclusivity and exclusivity performance in whole blood specimens. EBOV RNA, inactivated EBOV, and infectious EBOV were used as targets. The dynamic range of the assay, the inactivation of virus, and specimen stability were also evaluated. The lower limit of detection (LoD) for the assay using inactivated virus was estimated to be 73 copies/mL (95% CI: 51-97 copies/mL). The LoD for infectious virus was estimated to be 1 plaque-forming unit/mL, and for RNA to be 232 copies/mL (95% CI 163-302 copies/mL). The assay correctly identified five different Ebola viruses, Yambuku-Mayinga, Makona-C07, Yambuku-Ecran, Gabon-Ilembe, and Kikwit-956210, and correctly excluded all non-EBOV isolates tested. The conditions used by Xpert® Ebola for inactivation of infectious virus reduced EBOV titer by >6 logs. Conclusion: In summary, we found the Xpert1 Ebola Assay to have high analytical sensitivity and specificity for the detection of EBOV in whole blood. It offers ease of use, fast turnaround time, and remote monitoring. The test has an efficient viral inactivation protocol, fulfills inclusivity and exclusivity criteria, and has specimen stability characteristics consistent with the need for decentralized testing. The simplicity of the assay should enable testing in a wide variety of laboratory settings, including remote laboratories that are not capable of performing highly complex nucleic acid amplification tests, and during outbreaks where time to detection is critical.

UR - http://www.scopus.com/inward/record.url?scp=84955499230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955499230&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0142216

DO - 10.1371/journal.pone.0142216

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e0142216

ER -